IRIS
LUS, Giacomo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.072
NA - Nord America 6.603
AS - Asia 4.031
SA - Sud America 674
Continente sconosciuto - Info sul continente non disponibili 406
AF - Africa 54
OC - Oceania 5
Totale 21.845
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.426
RU - Federazione Russa 6.334
SG - Singapore 1.510
IE - Irlanda 956
IT - Italia 911
CN - Cina 860
HK - Hong Kong 579
BR - Brasile 578
VN - Vietnam 515
UA - Ucraina 430
GB - Regno Unito 425
DE - Germania 360
FR - Francia 169
KR - Corea 158
FI - Finlandia 128
IN - India 106
SE - Svezia 95
CA - Canada 87
TR - Turchia 76
GR - Grecia 69
JP - Giappone 58
AR - Argentina 48
MX - Messico 42
BD - Bangladesh 34
BE - Belgio 31
NL - Olanda 30
IQ - Iraq 25
PL - Polonia 23
HU - Ungheria 22
AT - Austria 21
IR - Iran 20
ID - Indonesia 16
EC - Ecuador 13
ES - Italia 13
PK - Pakistan 13
ZA - Sudafrica 13
CZ - Repubblica Ceca 11
CR - Costa Rica 10
MA - Marocco 10
CH - Svizzera 9
CO - Colombia 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
VE - Venezuela 7
EG - Egitto 6
LT - Lituania 6
CL - Cile 5
IL - Israele 5
PH - Filippine 5
RS - Serbia 5
SA - Arabia Saudita 5
UY - Uruguay 5
UZ - Uzbekistan 5
BB - Barbados 4
DO - Repubblica Dominicana 4
HN - Honduras 4
JM - Giamaica 4
JO - Giordania 4
KE - Kenya 4
KZ - Kazakistan 4
NI - Nicaragua 4
PY - Paraguay 4
RO - Romania 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AU - Australia 3
BG - Bulgaria 3
BO - Bolivia 3
ET - Etiopia 3
EU - Europa 3
GT - Guatemala 3
LB - Libano 3
MY - Malesia 3
PT - Portogallo 3
SV - El Salvador 3
TW - Taiwan 3
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
EE - Estonia 2
KG - Kirghizistan 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
AO - Angola 1
AZ - Azerbaigian 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
CY - Cipro 1
GA - Gabon 1
GP - Guadalupe 1
HR - Croazia 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
KY - Cayman, isole 1
Totale 21.430
Salva come PNG Salva come JPEG
Città #
Moscow 2.274
Dublin 955
San Jose 691
Santa Clara 687
Singapore 630
Jacksonville 597
Chandler 578
Hong Kong 562
Ashburn 535
Council Bluffs 358
Ho Chi Minh City 168
Seoul 155
Beijing 153
Princeton 149
Ann Arbor 146
Hefei 133
Milan 131
Hanoi 114
Dallas 112
Roxbury 112
Naples 110
Medford 99
Bremen 96
New York 93
Caserta 88
Los Angeles 74
The Dalles 70
Boardman 68
Munich 64
Wilmington 59
Woodbridge 57
Cambridge 51
Bengaluru 50
São Paulo 50
Memphis 39
San Mateo 39
Rome 34
Miano 33
Brussels 27
Atlanta 26
Da Nang 26
Norwalk 24
Nuremberg 24
Aversa 23
Chicago 23
Des Moines 23
Houston 23
Frankfurt am Main 21
Haiphong 21
Phoenix 21
Amsterdam 20
Toronto 20
Helsinki 19
Rio de Janeiro 19
Jinan 18
Warsaw 17
Tokyo 16
Montreal 15
Orem 15
San Francisco 15
Belo Horizonte 14
Carrboro 14
Chennai 14
Dong Ket 14
Nanjing 14
Tianjin 14
Turku 14
Brasília 13
Stockholm 13
Seattle 12
Boston 11
Guarulhos 11
Ninh Bình 11
Porto Alegre 11
Redwood City 11
Curitiba 10
Falkenstein 10
Luzzano 10
Mexico City 10
Mountain View 10
Thái Bình 10
Vienna 10
Baghdad 9
Columbus 9
Denver 9
Düsseldorf 9
Miami 9
Philadelphia 9
Auburn Hills 8
Biên Hòa 8
Bắc Ninh 8
Can Tho 8
Joinville 8
Kochi 8
London 8
Newark 8
Phú Nhuận 8
San José 8
Siano 8
Buffalo 7
Totale 11.280
Salva come PNG Salva come JPEG
Nome #
INSOLITO PNEUMOCEFALO IPERTESO DA OSTEOMA DEL SENO FRONTALE 239
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 214
Abnormal accumulation of tTGase products in muscle and erythrocytes of chorea-acanthocytosis patients 212
Modifications moleculaires au cours de la regeneration et reinnervation musculaires in vitro 190
A cluster of progranulin C157KfsX97 mutations in Southern Italy: clinical characterization and genetic correlations 189
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 183
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 178
Synergistic Interplay between Curcumin and Polyphenol-Rich Foods in the Mediterranean Diet: Therapeutic Prospects for Neurofibromatosis 1 Patients 175
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 171
Chronic HCV infection and neurological and psychiatric disorders: an overview. 170
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 168
Long-term effects of asymmetrical posture in boxing assessed by baropodometry 168
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 167
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 166
Biochemical and morphological evidences supporting the hypothesis of a role of TGase in the pathogenesis of chorea acanthocytosis (C-A) 166
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 161
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 160
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 160
A new tRNAHis mutation in the mtDNA results in mitochondrial encephalomyopathy by hampering ATP production 158
Biochemical and morphological evidences supporting the hypothesis of a role of Tgase in the pathogeneisi of Chorea-Acanthocytosis 158
Analisi in istofluorescenza di densità e distribuzione dei recettori per ConA e WGA in corso di rigenerazione e re-innervazione nel muscolo scheletrico di ratto ischemizzato e denervato, reversibilmente o irreversibilmente 157
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 155
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 155
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 154
A cluster of progranulin C157KfsX97 mutation in southern Italy- clinical characterization and genetic correlations 154
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 153
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 153
[Ambulatory monitoring of arterial pressure in the diagnosis and therapeutic evaluation of dysautonomic diseases: observations in a case of Shy-Drager syndrome] 152
Biochemical and morphological evidences supporting the hypothesis of a role of TGase in the pathogenesis of chorea acanthocytosis (C-A) 151
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 151
Rasagiline improves sleep disorders in Parkinson's disease 150
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 150
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 149
[Unusual histo-cytopathologic findings in a familial case of stiff spine syndrome] 148
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 148
Angiogenesis and Multiple Sclerosis Pathogenesis: A Glance at New Pharmaceutical Approaches 147
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 146
Myopathic changes in neurofibromatosis type 1 145
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 144
Malattie dei nervi periferici 143
An unusual phenotype of familial motor and sensory neuropathy with morphological features of HMSN1 142
Signs and symptoms of COVID-19 in patients with multiple sclerosis 141
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 141
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 140
CTG repeat number in the nonaffected allele of myotonic dystrophy patients is not critical for disease expression 140
Myoplasticity and myoregeneration; from molecular aspects to clinical perspectives 140
Disability assessment using Google Maps 140
Therapeutic Plasmapheresis: a revision of literature 139
39. Density and distribution of ConA and WGA receptors determined by histofluorescence analysis during degeneration, regeneration and reinnervation of the rat skeletal muscle following ischemia and reversible or irreversible denervation. , : , 139
Cecità e diplopia come espressione isolata di metastasi mesencefalica:considerazioni neuroradiologiche neurologiche e neurochirurgiche.A proposito di 2 casi 139
NEURO-DEGENERAZIONE CON ACCUMULO CEREBRALE DI FERRO TIPO 1 (NIBA TIPO1), UNA NUOVA FAMIGLIA CON MALATTIA DI HALLERVORDEN SPATZ A DECORSO CLINICO PROTRATTO 139
Unusual manifestation of vertebral osteoid osteoma: case report 137
Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. 137
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 136
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 135
A real-world study of alemtuzumab in a cohort of Italian patients 135
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 134
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. 133
CECITÀ E DIPLOPIA COME ESPRESSIONE ISOLATA DI METASTASI MESENCEFALICHE: CONSIDERAZIONI NEURORADIOLOGICHE, NEUROLOGICHE E NEUROCHIRURGICHE A PROPOSITO DI DUE CASI” 132
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 131
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis 131
Retrospective epidemiology of Duchenne muscular dystrophy in Molise 131
Reperti isto e citopatologici del tutto peculiari riscontrati in un caso familiare di sindrome della spina rigida 130
C’È UN GUADAGNO DIAGNOSTICO IN RM DELLE SACNSIONI TARDIVE OPO DOSE TRIPLA DI GADOLINIO NELL’IDENTIFICAZIONE DI PLACCHE ATTIVE DI SCLEROSI MULTIPLA? * Risultati preliminari 130
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 129
Fluctuations of MS births and UV-light exposure. 129
Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERFF phenotype. 129
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 129
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 129
Isolated transient blindness and isolated oculomotor nerve palsy secondary to single mesencephalic metastases: report of 2 cases 128
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 127
LA NEUROMIELITE OTTICA È UN’ ASSOCIAZIONE SINDROMICA COMUNE A PATOLOGIE ETEROGENEE 126
Clinical and Genetic Heterogeneity in a Large Family with Pseudoxanthoma Elasticum: MTHFR and SERPINE1 Variants as Possible Disease Modifiers in Developing Ischemic Stroke 126
Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study. 125
Autoantibodies in multiple sclerosis patients before and during IFN-β1b treatment: Are they correlated with the occurrence of autoimmune diseases? 124
CORRELATI CLINICO-STRUMENTALI IN UN CASO DI CREUTZFELD- JACOB A LUNGA SOPRAVVIVENZA. 124
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 123
Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, sex, and education 123
A narrative review of genetic and environmental factors and risk for multiple sclerosis. The design of the Italian multicentric PEDIGREE study 122
Dalla malattia di Schilder all’adrenoleucodistrofia; una breve storia di un secolo di ricerca neuropatologica clinica esemplare 122
La capacità rigenerativa del muscolo scheletrico danneggiato: studio sperimentale 122
Animal model to study factors influencing regeneration and direct innervation or neurotization of skeletal muscle 122
Migraine as possible red flag of PFO presence in suspected demyelinating disease 122
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 121
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders 121
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity 120
Prognostic indicators in pediatric clinically isolated syndrome 119
Histopathological heterogeneity and cytopathological similarity of findings in different muscles of two brothers affected by rigid spine syndrome 118
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 117
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 117
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 117
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study 116
Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy 116
Are giant axons a pathological marker of charcot-marie-tooth neuropathy type 2E? 116
Dalla malattia di Schilder alla adrenoleucodistrofia: una breve storia di un secolo di ricerca neuropatologica clinica esemplare 116
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 116
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 115
Quantitative Evaluation of Upright Posture by x-Ray and 3D Stereophotogrammetry with a New Marker Set Protocol in Late Onset Pompe Disease 115
Progressive rubella panencephalitis. Follow-up EEG study of a case 114
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 114
Totale 14.199
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.507
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.507
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022873 0 0 0 27 292 9 27 34 37 68 97 282
2022/20232.026 171 36 32 185 240 179 2 134 923 20 60 44
2023/2024731 70 21 48 56 252 60 10 25 6 3 57 123
2024/20252.675 6 45 40 74 399 406 298 201 393 420 235 158
2025/202610.736 323 424 556 524 895 5.915 639 477 379 276 201 127
2026/20271.961 83 310 771 797 0 0 0 0 0 0 0 0
Totale 21.845